Skip to main content

2 Result(s)

within Yoshimasa Shiraishi Remove this filter Biomedicine, general Remove this filter

and

  1. Article

    Open Access

    Phase II study of carboplatin/nab-paclitaxel/atezolizumab combination therapy for advanced nonsquamous non–small cell lung cancer patients with impaired renal function: RESTART trial

     First-line treatment of nonsquamous non–small cell lung cancer (NSCLC) has undergone a paradigm shift to platinum combination therapy together with immune checkpoint inhibitors (ICIs). However, phase III stud...

    Yoshimasa Shiraishi, Junji Kishimoto, Takayuki Shimose, Yukihiro Toi… in BMC Cancer (2022)

    Download PDF (887 KB) View Article

  2. No Access

    Article

    Association of immune-related adverse events with durvalumab efficacy after chemoradiotherapy in patients with unresectable Stage III non-small cell lung cancer

    Immune-related adverse events (irAEs) have been found to predict PD-L1 inhibitor efficacy in metastatic NSCLC. However, the relation of irAEs to clinical outcome for nonmetastatic NSCLC has remained unknown.

    Koji Haratani, Atsushi Nakamura, Nobuaki Mamesaya, Kenji Sawa… in British Journal of Cancer (2024)